A comparative proteomic study to characterize the vinblastine resistance in human ovarian cancer cells

Dawn P G Brown, Yesim Polar, Li Jiang, Jian Tan, Heather Ringham, Dariusz J. Janecki, Guihong Qi, Frank Witzmann, George W. Sledge, Mu Wang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Drug resistance is a major impediment to the successful treatment of human cancers, including ovarian cancer. Vinblastine (VLB), an antimicrotubule agent, is one of the chemotherapeutic drugs that exhibit resistance in ovarian cancer patients. To determine the protein factors that are involved in vinblastine resistance in human ovarian cancer cells, a combination of sample pre-fractionation and high-resolution 2-DE proteomic analysis was performed. Approximately 1200 proteins were detected and quantitatively compared in both nuclear/membrane and cytosolic fractions. Sixty-nine proteins from the nuclear/membrane fraction showed altered expression levels, whereas 59 were altered in the cytosolic fraction between SKOV3 (vinblastine-sensitive) and SKVLB (vinblastine-resistant) cell lines. These proteins include membrane-associated, chromatin remodeling, cytoskeletal, and microtubule-associated proteins as well as others that regulate signal transduction. This study not only demonstrates a novel understanding of the mechanism of drug resistance but also provides a valuable resource for future studies on drug resistance to vinblastine. In addition, it also represents a good example of how to increase the protein dynamic range and reduce sample complexity using currently available tools.

Original languageEnglish
Pages (from-to)18-31
Number of pages14
JournalProteomics - Clinical Applications
Volume1
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Vinblastine
Proteomics
Ovarian Neoplasms
Drug Resistance
Cells
Nuclear Envelope
Membranes
Pharmaceutical Preparations
Proteins
Signal transduction
Chromatin Assembly and Disassembly
Microtubule-Associated Proteins
Fractionation
Nuclear Proteins
Chromatin
Signal Transduction
Membrane Proteins
Cell Line
Neoplasms

Keywords

  • Drug resistance
  • Mass spectrometry
  • Ovarian cancer
  • Pre-fractionation

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

A comparative proteomic study to characterize the vinblastine resistance in human ovarian cancer cells. / Brown, Dawn P G; Polar, Yesim; Jiang, Li; Tan, Jian; Ringham, Heather; Janecki, Dariusz J.; Qi, Guihong; Witzmann, Frank; Sledge, George W.; Wang, Mu.

In: Proteomics - Clinical Applications, Vol. 1, No. 1, 01.2007, p. 18-31.

Research output: Contribution to journalArticle

Brown, Dawn P G ; Polar, Yesim ; Jiang, Li ; Tan, Jian ; Ringham, Heather ; Janecki, Dariusz J. ; Qi, Guihong ; Witzmann, Frank ; Sledge, George W. ; Wang, Mu. / A comparative proteomic study to characterize the vinblastine resistance in human ovarian cancer cells. In: Proteomics - Clinical Applications. 2007 ; Vol. 1, No. 1. pp. 18-31.
@article{5deb86feb9b14791ae5e5e50ecbdfc07,
title = "A comparative proteomic study to characterize the vinblastine resistance in human ovarian cancer cells",
abstract = "Drug resistance is a major impediment to the successful treatment of human cancers, including ovarian cancer. Vinblastine (VLB), an antimicrotubule agent, is one of the chemotherapeutic drugs that exhibit resistance in ovarian cancer patients. To determine the protein factors that are involved in vinblastine resistance in human ovarian cancer cells, a combination of sample pre-fractionation and high-resolution 2-DE proteomic analysis was performed. Approximately 1200 proteins were detected and quantitatively compared in both nuclear/membrane and cytosolic fractions. Sixty-nine proteins from the nuclear/membrane fraction showed altered expression levels, whereas 59 were altered in the cytosolic fraction between SKOV3 (vinblastine-sensitive) and SKVLB (vinblastine-resistant) cell lines. These proteins include membrane-associated, chromatin remodeling, cytoskeletal, and microtubule-associated proteins as well as others that regulate signal transduction. This study not only demonstrates a novel understanding of the mechanism of drug resistance but also provides a valuable resource for future studies on drug resistance to vinblastine. In addition, it also represents a good example of how to increase the protein dynamic range and reduce sample complexity using currently available tools.",
keywords = "Drug resistance, Mass spectrometry, Ovarian cancer, Pre-fractionation",
author = "Brown, {Dawn P G} and Yesim Polar and Li Jiang and Jian Tan and Heather Ringham and Janecki, {Dariusz J.} and Guihong Qi and Frank Witzmann and Sledge, {George W.} and Mu Wang",
year = "2007",
month = "1",
doi = "10.1002/prca.200600171",
language = "English",
volume = "1",
pages = "18--31",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "1",

}

TY - JOUR

T1 - A comparative proteomic study to characterize the vinblastine resistance in human ovarian cancer cells

AU - Brown, Dawn P G

AU - Polar, Yesim

AU - Jiang, Li

AU - Tan, Jian

AU - Ringham, Heather

AU - Janecki, Dariusz J.

AU - Qi, Guihong

AU - Witzmann, Frank

AU - Sledge, George W.

AU - Wang, Mu

PY - 2007/1

Y1 - 2007/1

N2 - Drug resistance is a major impediment to the successful treatment of human cancers, including ovarian cancer. Vinblastine (VLB), an antimicrotubule agent, is one of the chemotherapeutic drugs that exhibit resistance in ovarian cancer patients. To determine the protein factors that are involved in vinblastine resistance in human ovarian cancer cells, a combination of sample pre-fractionation and high-resolution 2-DE proteomic analysis was performed. Approximately 1200 proteins were detected and quantitatively compared in both nuclear/membrane and cytosolic fractions. Sixty-nine proteins from the nuclear/membrane fraction showed altered expression levels, whereas 59 were altered in the cytosolic fraction between SKOV3 (vinblastine-sensitive) and SKVLB (vinblastine-resistant) cell lines. These proteins include membrane-associated, chromatin remodeling, cytoskeletal, and microtubule-associated proteins as well as others that regulate signal transduction. This study not only demonstrates a novel understanding of the mechanism of drug resistance but also provides a valuable resource for future studies on drug resistance to vinblastine. In addition, it also represents a good example of how to increase the protein dynamic range and reduce sample complexity using currently available tools.

AB - Drug resistance is a major impediment to the successful treatment of human cancers, including ovarian cancer. Vinblastine (VLB), an antimicrotubule agent, is one of the chemotherapeutic drugs that exhibit resistance in ovarian cancer patients. To determine the protein factors that are involved in vinblastine resistance in human ovarian cancer cells, a combination of sample pre-fractionation and high-resolution 2-DE proteomic analysis was performed. Approximately 1200 proteins were detected and quantitatively compared in both nuclear/membrane and cytosolic fractions. Sixty-nine proteins from the nuclear/membrane fraction showed altered expression levels, whereas 59 were altered in the cytosolic fraction between SKOV3 (vinblastine-sensitive) and SKVLB (vinblastine-resistant) cell lines. These proteins include membrane-associated, chromatin remodeling, cytoskeletal, and microtubule-associated proteins as well as others that regulate signal transduction. This study not only demonstrates a novel understanding of the mechanism of drug resistance but also provides a valuable resource for future studies on drug resistance to vinblastine. In addition, it also represents a good example of how to increase the protein dynamic range and reduce sample complexity using currently available tools.

KW - Drug resistance

KW - Mass spectrometry

KW - Ovarian cancer

KW - Pre-fractionation

UR - http://www.scopus.com/inward/record.url?scp=48149098396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48149098396&partnerID=8YFLogxK

U2 - 10.1002/prca.200600171

DO - 10.1002/prca.200600171

M3 - Article

C2 - 21136609

AN - SCOPUS:48149098396

VL - 1

SP - 18

EP - 31

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 1

ER -